<p><strong>Join us for a fascinating conversation with Dr. Subhoja Chakraborty from the University of Central Florida, whose cutting-edge research targets the global challenge of malaria drug resistance. Dr. Chakraborty shares her journey from structure-based drug design during her PhD to her recent collaborative work repurposing human kinase inhibitors as rapid, selective antimalarials against drug-resistant Plasmodium falciparum strains.</strong></p><h4><strong>In this episode, you'll learn:</strong></h4><ul><li>How structure-guided approaches reveal potential drug targets, including cysteine proteases like falcipain-2, and kinases implicated in malaria's complex life cycle.</li><li>The power of repurposing kinase inhibitors originally developed for cancer and other diseases, focusing on compound 12, which blocks hemozoin formation and protein kinase 6—key steps in parasite survival.</li><li>Lab techniques such as affinity, gel filtration, and size exclusion chromatography for recombinant protein purification—and how troubleshooting is crucial for high-yield, stable complexes.</li><li>Advances in mass spectrometry for characterizing protein interactions, validating drug targets, and mapping molecular pathways pivotal to malaria therapeutics.</li><li>Tips and lessons for new researchers facing the challenges of sample preparation, complex protocols, and working as part of a collaborative team.</li></ul><p>Dr. Chakraborty’s insights bridge the gap between basic science and translational drug discovery, offering hope for more effective, targeted malaria treatments in a world where resistance to frontline therapies threatens millions.</p><h4><strong>Referenced Papers:</strong></h4><ul><li>"Plasmodium falciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activity" (Cell Chemical Biology, 2025)</li><li>"New insights of falcipain 2 structure from Plasmodium falciparum 3D7 strain" (BBRC, 2022)</li><li>"Structure-Based Optimization of Protease−Inhibitor Interactions to Enhance Specificity of Human Stefin‑A against Falcipain‑2 from the Plasmodium falciparum 3D7 Strain" (Biochemistry, 2023)</li></ul><p>If you’re a student, scientist, or simply passionate about advances in infectious disease research, this episode offers actionable insights, inspiring advice, and a front-row seat to innovation in combating malaria.</p><h3><strong>Video Transcription</strong></h3><h4><strong>From Structural Biology to Drug Discovery: Chromatography and Mass Spectrometry in Malaria Research</strong></h4><h5><strong>Introduction</strong></h5><p>In this discussion, Subhoja shares insights into her research journey, focusing on malaria drug discovery and the role of modern analytical techniques in biological and biomedical research. The conversation is aimed primarily at undergraduate students and early-career researchers interested in chemistry, biotechnology, and life sciences.</p><h5><strong>Research Focus: Malaria Drug Discovery and Kinase Targets</strong></h5><p>Subhoja is currently involved in malaria drug discovery research at the University of Central Florida, where she has been working since beginning her postdoctoral position two years ago. Her earlier PhD research focused on structure-based drug design in malaria, using a combination of in silico approaches, recombinant protein expression, and X-ray crystallography to determine precise three-dimensional structures of target proteins and their inhibitors.</p><p>This structural perspective provided a foundation for her current work, which centers on drug discovery through compound screening and repurposing. A recent publication from her laboratory explores the use of repurposed mammalian CDK-like kinase inhibitors as potential antimalarial agents. While such kinase inhibitors are well known in cancer and cardiovascular research, their application to malaria targets represents a novel and promising approach.</p><p>Kinases are attractive drug targets because of their central role in cell signaling and growth pathways. By targeting specific kinases involved in different stages of the malaria parasite life cycle—whether asexual growth, gametocytogenesis, or differentiation—it may be possible to significantly inhibit parasite growth and progression.</p><h5><strong>Chromatography in Protein Expression and Purification Workflows</strong></h5><p>Chromatography plays a critical role throughout Subhoja’s research. Her experience spans from basic chromatography techniques during her early training to advanced protein purification workflows using affinity chromatography, gel filtration (size exclusion chromatography), and ion exchange chromatography.</p><p>Recombinant proteins are routinely purified using affinity resins such as nickel or cobalt, followed by further purification to remove contaminants. Fast Protein Liquid Chromatography (FPLC) enables compact, stepwise purification workflows suitable for producing proteins for in vitro assays.</p><p>A recurring challenge in this process is the expression of high-molecular-weight proteins, which often accumulate in insoluble fractions or inclusion bodies. Careful selection of expression vectors, host systems, and induction conditions is therefore essential to maximize yield and solubility.</p><h5><strong>Integrating Size Exclusion Chromatography into the Workflow</strong></h5><p>Size exclusion chromatography (SEC) is typically used after affinity purification to further improve protein purity. Following elution with imidazole or glutathione, desalting is required to prevent buffer components from interfering with downstream assays. This is often achieved using desalting columns such as G-25 or PD-10.</p><p>To remove lower-molecular-weight contaminants, finer SEC media—such as Superdex or Sephacryl columns—are employed. Concentration steps using molecular-weight cut-off filters are then applied to obtain the desired protein concentration for functional studies.</p><p>These iterative purification and troubleshooting steps are a routine part of protein biochemistry and reflect the importance of methodical optimization and careful validation.</p><h5><strong>The Role of Mass Spectrometry in Biomolecular Characterization</strong></h5><p>Mass spectrometry is a key analytical tool in Subhoja’s research pipeline, particularly for target identification and validation. In both malaria and cancer research, MS is used alongside chromatography, immunoprecipitation, and pull-down assays to study protein interactions and molecular recognition events.</p><p>Affinity-based mass spectrometry enables the identification of binding partners and interactors, whether studying proteins, long non-coding RNAs, or protein complexes. Techniques such as native MS, tandem affinity purification, and proximity labeling (e.g., TurboID-based workflows) provide deeper insights into molecular networks and signaling pathways.</p><p>These approaches are essential for understanding how candidate drug targets function within complex biological systems.</p><h5><strong>Sample Preparation Challenges in Biological Research</strong></h5><p>Sample preparation remains one of the most challenging aspects of biological experimentation. Whole-cell lysates contain proteases, nucleases, and other components that can rapidly degrade target molecules. Preventing degradation requires minimizing preparation time, maintaining low temperatures, and using appropriate inhibitor cocktails.</p><p>Reproducibility is also critical: biological experiments require multiple replicates, and variability is often unavoidable. Careful handling, protocol optimization, and continuous troubleshooting are essential to ensure reliable results, whether preparing samples for chromatography, mass spectrometry, sequencing, or immunoprecipitation.</p><h5><strong>Advances in Chromatography and MS for Malaria Research</strong></h5><p>Modern advances in chromatography and mass spectrometry significantly enhance malaria research by enabling precise target identification, quantification, and functional characterization. Drug discovery workflows begin with construct design and recombinant expression, followed by purification and interaction studies.</p><p>In malaria research, stage-specific parasite biology requires careful extraction and analysis of proteins from different life cycle stages. Tandem affinity MS, immunoprecipitation, and in vivo validation studies help confirm target relevance and therapeutic potential.</p><p>Recent work on repurposed kinase inhibitors has shown promising results, including inhibition of hemozoin formation—a key detoxification pathway for the malaria parasite—highlighting the potential of such compounds for further development.</p><h5><strong>Malaria, Drug Resistance, and Global Impact</strong></h5><p>Malaria remains a major global health burden, with over 600,000 deaths annually and widespread drug resistance complicating treatment. Artemisinin resistance, particularly associated with mutations in the K13 propeller domain, has driven the search for new targets and therapies.</p><p>During her PhD, Subhoja focused on falcipain-2, a cysteine protease involved in hemoglobin degradation within the parasite. This pathway is critical for parasite survival and has emerged as a promising drug target. Her work revealed that falcipain-2 operates within a larger protein complex responsible for hemoglobin processing and amino acid release.</p><p>Understanding these molecular mechanisms is essential for developing robust, stage-specific antimalarial strategies.</p><h5><strong>Advice for Early-Career Researchers</strong></h5><p>For researchers just starting out, Subhoja emphasizes the importance of hands-on experience. Working directly with cells, lysates, and analytical tools is essential for truly understanding experimental systems. Failure is an inherent part of research, and perseverance is key.</p><p>Motivation, teamwork, careful sample handling, and thorough preparation all contribute to long-term success. Reading extensively, critically evaluating one’s own work, and appreciating incremental progress are vital aspects of a sustainable research career.</p><p>Every successful experiment—no matter how small—represents meaningful progress and contributes to the broader goals of science and medicine.</p><h5><strong>Closing Remarks</strong></h5><p>The discussion highlights how interdisciplinary approaches combining chromatography, mass spectrometry, structural biology, and biochemistry are driving advances in malaria drug discovery. Through careful experimental design, analytical rigor, and collaborative teamwork, researchers can address complex biological challenges and contribute to global health solutions.</p><blockquote><p><strong>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</strong></p></blockquote><blockquote><h4><strong>Concentrating on Chromatography Podcast</strong></h4><p>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!</p><p>You can find <strong>Concentrating on Chromatography Podcast </strong>in podcast apps:</p><ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL"><strong>Spotify</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185"><strong>Apple podcast</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography"><strong>podscan</strong></a></li></ul><p>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos"><strong>YouTube channel</strong></a></p></blockquote>

Affinity, Gel Filtration, Size Exclusion Chromatography: Repurposing Kinase Inhibitors for Malaria

<p><strong>In the week of February 9, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.</strong></p><blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars"><strong>👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</strong></a></h4><p><strong>👉 Search and filter in the largest global database</strong> with over <strong>5 000 GC, LC, MS and spectroscopy webinars</strong>.</p></blockquote><h5><strong>1. SelectScience: High-Throughput Stability Screening Strategies for Antibody Formulation</strong></h5><ul><li>Tu, 10.2.2026 17:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5807">Registration</a></li></ul><p>Learn how high-throughput DLS/SLS and rapid-screening DSC accelerate stability assessment of high-concentration antibody formulations, enabling faster, data-driven biologics development.</p><h5><strong>2. Phenomenex: Big Scale, Big Wins – Prep Chromatography Explained</strong></h5><ul><li>We, 11.2.2026 10:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5793">Registration</a></li></ul><p>Learn how to scale analytical methods to preparative HPLC, optimize loading capacity, and understand the limits of preparative columns for pharmaceutical applications.</p><h5><strong>3. ALS Czech Republic: PFAS in Food &amp; Food Contact Material</strong></h5><ul><li>We, 11.2.2026 15:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5816">Registration</a></li></ul><p>Get a practical overview of PFAS in food and food contact materials, including EU and US regulations, key analytical challenges, and reliable PFAS testing strategies.</p><h5><strong>4. New Food Magazine: The Science of Next-Gen Ingredients – Fermentation, Formulation and Function</strong></h5><ul><li>We, 11.2.2026 16:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5720">Registration</a></li></ul><p>Explore how fermentation-driven innovation is transforming functional food ingredients and how advanced analytics optimize flavour, functionality, and stability.</p><h5><strong>5. SCIEX: Accurate Mass Fundamentals – Interpreting and Applying Your Data</strong></h5><ul><li>We, 11.2.2026 19:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5772">Registration</a></li></ul><p>Session 3 focuses on interpreting and applying accurate mass data to confirm compound identity, move beyond basic quantitation, and troubleshoot results for confident reporting.</p><h5><strong>6. Agilent Technologies: Process Analytical Techniques – Online HPLC for Real-Time Monitoring and Control of Bioprocesses</strong></h5><ul><li>Th, 12.2.2026 06:30 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5834">Registration</a></li></ul><p>Discover how PAT HPLC enables near-real-time monitoring of critical quality attributes in bioprocessing, with a case study on charge-variant control by cation-exchange chromatography.</p><h5><strong>7. Thermo Fisher Scientific: Introducing the Orbitrap Excedion Pro Hybrid MS</strong></h5><ul><li>Th, 12.2.2026 11:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5889">Registration</a></li></ul><p>Discover the new Orbitrap Exploris Pro with expanded ETD/EThcD capabilities for confident biopharmaceutical characterization, including intact proteins, PTMs, ADCs, and large biomolecules.</p><h5><strong>8. Waters Corporation: Planning Your NuGenesis Upgrade – Insights and Best Practices for a Smooth Transition</strong></h5><ul><li>Th, 12.2.2026 19:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5833">Registration</a></li></ul><p>Learn how to plan a successful NuGenesis upgrade, transition to Windows 11, and unlock new capabilities such as dashboards for real-time operational insights.</p><h5><strong>9. Thermo Fisher Scientific: Comprehensive Analytical Strategies for Peptide Therapeutics and GLP-1 Agonists with Agilent</strong></h5><ul><li>Th, 12.2.2026 19:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5814">Registration</a></li></ul><p>Explore analytical workflows for peptide therapeutics, including method development, peptide mapping, GLP-1 QC, and LC-MS strategies across Agilent platforms.</p><h5><strong>10. Agilent Technologies: Moving from R&amp;D and Limited QC on a UV-Vis-NIR Instrument to Large-Scale QC Using an Autosampler</strong></h5><ul><li>Th, 12.2.2026 20:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/2104">Registration</a></li></ul><p>This webinar covers practical aspects of adding and using an autosampler to maximize UV-Vis-NIR QC workflows at scale.</p><h5><strong>11. Agilent Technologies: LC Method Transfer – Hidden Challenges &amp; Absolute Solution</strong></h5><ul><li>Fr, 13.2.2026 06:30 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5787">Registration</a></li></ul><p>Discover why LC method transfer between legacy and modern systems is challenging, which hidden parameters affect retention and peak shape, and how to achieve robust, reliable results.</p>

Webinars LabRulezLCMS Week 07/2026

<p><strong>Charge detection mass spectrometry (CDMS) allows direct mass determination of individual ions and is increasingly used to study heterogeneous biological samples. This work demonstrates the use of Orbitrap-based CDMS/Direct Mass Technology (DMT) for quantitative analysis of transthyretin (TTR) tetramer samples below 100 kDa, extending CDMS beyond its traditional qualitative role.</strong></p><p>DMT resolved wild-type and C-terminally modified TTR homotetramers, as well as hybrid tetramers, enabling kinetic analysis of subunit exchange and stability. The approach also quantified thyroxine binding to TTR variants, revealing differences in binding affinity linked to C-terminal modification. By separating overlapping m/z signals through charge measurement, CDMS enables accurate mass and abundance determination, highlighting its potential for quantitative analysis of complex protein systems.</p><blockquote><h4><strong>The original article</strong></h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771"><strong>Dissecting Heterogeneous Populations of Protein-Complex Samples Using Direct Mass Technology</strong></a></h4><p>Robert L. Rider, Jared Hampton, Zhenyu Xi, Carter Lantz, Sangho D. Yun, Weijing Liu, Rosa Viner, Arthur Laganowsky, and David H. Russell*</p><p>Anal. Chem. 2025, 97, 49, 27057–27063</p><p><a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1021/acs.analchem.5c05771">https://doi.org/10.1021/acs.analchem.5c05771</a></p><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><p><strong>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.</strong></p><p>Transthyretin (TTR) is a homotetrameric transport protein that circulates in plasma and cerebrospinal fluid, delivering thyroxine (T<sub>4</sub>) and retinol-binding protein–vitamin A complexes. <a href="javascript:void(0);">(1)</a> The stability of the TTR tetramer is central to its physiological role because dissociation into monomers can initiate misfolding and amyloid formation, leading to systemic or hereditary transthyretin amyloidosis. <a href="javascript:void(0);">(2)</a> Subunit exchange between wild-type (WT) and variant TTR proteoforms, including disease-associated mutations such as V30M and V122I, have been implicated in amyloid progression by generating hybrid tetramers (tetramers containing WT and mutant subunits) with altered stabilities. <a href="javascript:void(0);">(3,4)</a> Ligand binding, particularly at the two thyroxine-binding sites located at the dimer–dimer interface, can kinetically stabilize the tetramer and modulate amyloidogenicity. <a href="javascript:void(0);">(5,6)</a> Accurate measurement of both subunit exchange kinetics and ligand binding stoichiometry is therefore critical for elucidating the TTR dynamics and stability.</p><p>Affinity or sequence tags are widely employed in protein expression, purification, or detection. <a href="javascript:void(0);">(7,8)</a> While these tags are often assumed to be inert, their influence on protein structure and dynamics are rarely examined in detail. <a href="javascript:void(0);">(9,10)</a> Protein tags at the N- and C-terminus of TTR have been shown to have differing gas phase stabilities from those of WT-TTR. <a href="javascript:void(0);">(11)</a> The C-terminus is of particular interest because this region participates in the dimer–dimer interface that governs tetramer stability. <a href="javascript:void(0);">(11,12)</a> Characterizing how the C-terminal tag (CT) (-ASGENLFYQ) affects TTR’s solution stability and ligand binding is not only relevant for understanding TTR dynamics but also provides an example of how expression tags can alter protein dynamics. <a href="javascript:void(0);">(13)</a></p><p>Native mass spectrometry (nMS) has been invaluable for characterizing protein complexes, <a href="javascript:void(0);">(14)</a> yet conventional nMS often struggles with heterogeneous samples where overlapping charge state distributions and adduct heterogeneity limit resolution and quantitation. <a href="javascript:void(0);">(15)</a> Charge detection mass spectrometry (CDMS) addresses these limitations by independently measuring the charge and <i>m</i>/<i>z</i> of individual ions, enabling the direct determination of molecular mass and abundance. Development of CDMS has largely focused on achieving higher mass resolution <a href="javascript:void(0);">(16)</a> and extending measurements toward assemblies into the GDa range. <a href="javascript:void(0);">(17,18)</a> However, there is untapped utility for CDMS experiments other than mass and proteoform determination. Jordan et al. showed the capability to assess conformational heterogeneity of mAb aggregates using the added charge dimension that CDMS provides. <a href="javascript:void(0);">(19)</a> The current work demonstrates that CDMS can separate proteoforms with overlapping <i>m</i>/<i>z</i> values based on charge and quantify their relative abundances in complex mixtures. While nMS is already a highly quantitative technique, our results establish CDMS as an equally powerful tool for quantitative analysis in heterogeneous systems. <a href="javascript:void(0);">(20,21)</a></p><p>Here, we apply Orbitrap-based CDMS/Direct Mass Technology (DMT) using the selective temporal overview of resonant ions (STORI) approach <a href="javascript:void(0);">(22,23)</a> to quantitatively compare WT-TTR and CT-TTR, focusing on two biologically relevant properties: tetramer stability assessed via subunit exchange kinetics and ligand-binding affinity. Conventional nMS cannot fully resolve the overlapping charge states of WT- and CT-TTR or their ligand-bound states. However, DMT can resolve these species by directly measuring the mass (<i>m</i>/<i>z</i> × charge), enabling quantitation of all proteoforms. The data reveal that the CT tag alters tetramer stability and thyroxine-binding affinity, demonstrating the structural sensitivity of TTR to modifications at its C-terminus. More broadly, this work demonstrates the impact that protein tags can have on native protein interactions and highlights the broader utility of quantitative CDMS for probing heterogeneous biological samples.</p><h4><strong>Experimental Section</strong></h4><h5><strong>Data Collection</strong></h5><p>All experiments were conducted on a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/560"><strong>Thermo Scientific Q-Exactive UHMR</strong></a> with added DMT capabilities (Bremen, Germany). Before DMT, mass spectra were collected at various resolving powers (6–200k) for each sample, with the instrument parameters reported in the Supporting Information (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Table S1</a>). For DMT experiments, the trapping gas pressure in the HCD cell was reduced to 0.3–0.8 to attenuate the signal intensity to a single ion level, as well as decreasing the UHV pressure to assist ion retention through the entire transient of Orbitrap analysis. We observed no significant difference between mass spectra collected at various HCD cell pressures (Supporting Information, <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Figure S1</a>). For DMT collection, automated ion control (AIC) and 100% target density were used with 200k resolving power.</p><h4><strong>Results and Discussion</strong></h4><p>CDMS has emerged as a powerful tool for analyzing heterogeneous biomolecular samples, enabling accurate, direct mass determination by simultaneously measuring the charge and <i>m</i>/<i>z</i> for individual ions. While CDMS has been widely applied for qualitative analyses, its potential for quantitative and less than MDa applications remains underexplored. <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>A shows the theoretical mass spectrum of WT-TTR (14+ to 16+) and CT-TTR (15+ to 17+) homotetramers, where the two proteoforms become increasingly resolved as the charge states increase (&lt;3900 <i>m</i>/<i>z</i>). <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>B zooms in on the 14+ (WT) and 15+ (CT) charge states, highlighting their strong overlap, which prevents accurate deconvolution of the proteoforms by conventional methods. <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>C displays theoretical distributions for 0, 1, and 2 T<sub>4</sub> bound states of both WT- and CT-TTR tetramers, where &lt;3900 <i>m</i>/<i>z</i> has observable separation between all proteoforms. However, for the 14+ and 15+ charge states of WT- and CT-TTR, respectively, the 0 T<sub>4</sub>- and 1 T<sub>4</sub>-bound populations overlap (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig1">Figure 1</a>D). Furthermore, commonly adducted species (Na<sup>+</sup>, K<sup>+</sup>, and Zn<sup>2+</sup>) observed in experimental spectra broaden these distributions, making it increasingly difficult to distinguish and deconvolute the proteoforms (see <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Figure S2</a>). Here, we employ Orbitrap-based CDMS/DMT to overcome this <i>m</i>/<i>z</i> overlap to resolve and quantify hybrid tetramer formation and T<sub>4</sub> binding.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2025_97_49_27057_27063_Figure_1_A_Theoretical_mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_47232849d9.jpg" alt="Anal. Chem. 2025, 97, 49, 27057–27063: Figure 1. (A) Theoretical mass spectra of WT-TTR and CT-TTR homotetramers. (B) Zoomed-in view of the 14+ WT-TTR and 15+ CT-TTR distributions to show the large overlap of the proteoforms. (C) Theoretical mass spectra of WT-TTR and CT-TTR homotetramers with thyroxine (T4) binding. (D) Zoomed-in view of the 14+ WT-TTR and 15+ CT-TTR distributions where the 0 and 1 T4 have overlapping distributions. These theoretical distributions do not contain any commonly adducted species (Na+, K+, Zn2+), which broaden the distributions and create more overlap even for the proteoforms in the range 3300–3900 m/z (see Figure S2)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2025_97_49_27057_27063_Figure_1_A_Theoretical_mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_47232849d9.jpg 187w," sizes="100vw" width="1417" height="1182"></p><h5><strong>Thyroxine Binding to TTR Homotetramers</strong></h5><p>Thyroxine is the less active form of a thyroid hormone important for metabolism that binds to TTR for transport throughout plasma and cerebral spinal fluid. <a href="javascript:void(0);">(31)</a> Turnover of T<sub>4</sub> into T<sub>3</sub> (active) occurs after dissociation, where it can then modulate gene expression via binding to nuclear receptors. <a href="javascript:void(0);">(32)</a> The TTR tetramer gains substantial stability as it binds up to 2 T<sub>4</sub> at the tetramer interface, decreasing tetramer dissociation and SUE. <a href="javascript:void(0);">(33)</a> This has been shown previously to decrease the amyloidogenic rate of TTR, which led to tafamidis (similar in structure to T<sub>4</sub>) to be designed and is currently the only drug that is approved for clinical treatment of TTR amyloidosis. <a href="javascript:void(0);">(34)</a> Measuring the difference in binding affinity between TTR proteoforms may provide insight into regions of TTR or TTR intermolecular/intramolecular interactions that are important for binding of small molecules such as tafamidis and T<sub>4</sub>.</p><p>DMT was further applied to quantify T<sub>4</sub> binding to WT- and CT-TTR homotetramers, highlighting the technique’s utility in probing protein–ligand interactions. <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig3">Figure 3</a>A shows a representative mass spectrum of TTR homotetramers in the presence of T<sub>4</sub>. While ligand-bound species can be observed, homotetramers cannot be confidently resolved across the entire 3000–5000 <i>m</i>/<i>z</i> range. By leveraging the charge-resolving capabilities of DMT, we achieve separation of the homotetramers (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05771#fig3">Figure 3</a>B,C) and the 0, 1, and 2 ligand-bound states. The 2D plot clearly shows the gain in resolution achieved when charge is simultaneously measured with <i>m</i>/<i>z</i> by separating the 14+ and 15+ charge states for WT and CT, respectively, in the range 3900–4200 <i>m</i>/<i>z</i>. Additionally, using ion mobility does not provide the same kind of 2D resolution due to the similarity in arrival times for the homotetramer proteoforms, as evidenced by <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05771/suppl_file/ac5c05771_si_001.pdf">Figures S4 and S5</a> (see the Supporting Information). These data provide evidence that when ion mobility is able to separate out species that overlap in <i>m</i>/<i>z</i> yet differ in mobility, CDMS could be an alternative or used complementarily since the species likely also differ in charge.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2025_97_49_27057_27063_Figure_3_A_Mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_with_thyroxine_binding_61b1e98a94.jpg" alt="Anal. Chem. 2025, 97, 49, 27057–27063: Figure 3. (A) Mass spectra of WT-TTR and CT-TTR homotetramers with thyroxine binding. Ligand binding can be resolved, but homotetramers cannot be confidently identified. Charge states labeled are for WT; CT is always one charge state higher at the same m/z range. (B) DMT heatmap resolving WT-TTR and CT-TTR homotetramers with the additional measurement of charge. (C) Deconvoluted mass spectrum from DMT analysis. Both homotetramers and their ligand binding are resolved, and fit for analysis is shown in red. (D) Mole fraction of each homotetramer and their thyroxine binding species. Error bars represent the standard deviation of replicates (n = 3). The significance for each ligand state is in respect to the left adjacent state. *p &lt; 0.05." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2025_97_49_27057_27063_Figure_3_A_Mass_spectra_of_WT_TTR_and_CT_TTR_homotetramers_with_thyroxine_binding_61b1e98a94.jpg 181w," sizes="100vw" width="1266" height="1094"></p><h4><strong>Conclusion</strong></h4><p>This work demonstrates that quantitatively, Orbitrap-based CDMS/DMT can determine differences in protein-complex stability and ligand binding. By directly comparing WT- with CT-TTR, we show that the CT tag accelerates tetramer dissociation while enhancing T<sub>4</sub> binding affinity. These results indicate that the C-terminus, located at the dimer–dimer interface, plays a more significant role in TTR stability and ligand recognition than previously appreciated. <a href="javascript:void(0);">(12)</a> Even the addition of a short peptide sequence perturbs noncovalent interactions at the interface, likely altering solvent accessibility, and the dynamics of the thyroxine binding channel. <a href="javascript:void(0);">(37,54)</a> Such findings underscore the importance of evaluating how seemingly minor sequence modifications, such as affinity tags, can influence fundamental biophysical properties.</p><p>Beyond TTR, this work positions quantitative CDMS as a broadly applicable strategy for analyzing heterogeneous protein systems, where charge domain separation overcomes the resolution limits of <i>m</i>/<i>z</i> domain measurements in traditional nMS experiments. While much of the field has emphasized extending CDMS to ultrahigh masses and maximal resolution, <a href="javascript:void(0);">(16,18)</a> our results highlight the underexplored potential of applying the method in the 1000–10,000 <i>m</i>/<i>z</i> range common to nMS experiments. This capability is directly relevant to heterogeneous membrane protein complexes, which often display broad distributions of oligomeric states, PTMs, lipid, and ligand adducts that complicate spectra. <a href="javascript:void(0);">(48,55)</a> Similarly, mAbs can oligomerize and exhibit mass heterogeneity from variable glycosylation, affecting pharmacokinetics, effector function, and stability. <a href="javascript:void(0);">(19)</a> CDMS may resolve and quantify such proteoforms in a single experiment without the need for charge reduction or chemical derivatization. <a href="javascript:void(0);">(48,56,57)</a></p>

Dissecting Heterogeneous Populations of Protein-Complex Samples Using Direct Mass Technology

Article

Webinars

Video

Scientists

Scientific article

Interview

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Thermo Scientific Acclaim VANQUISH C18 UHPLC Columns

Achieve even greater power of separation, speed, and throughput using Thermo Scientific Acclaim VANQUISH C18 UHPLC columns.

<p><strong>Achieve even greater power of separation, speed, and throughput using Thermo Scientific™ Acclaim™ VANQUISH™ C18 UHPLC columns. These reversed phase columns were developed in conjunction with the </strong><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?category=40&amp;manufacturerItems=3&amp;search=vanquish"><strong>Vanquish UHPLC system</strong></a><strong> to take advantage of the system's extended pressure capabilities and robustness. The result is a new level of separation, speed and throughput that solve analytical challenges in liquid chromatography (LC) and LC-MS analyses.</strong></p><h5><strong>Delivering Powerful Separations</strong></h5><p>The expanded range of Thermo Scientific™ Accucore™ Vanquish™ and Acclaim VANQUISH UHPLC columns offer a wider range of selectivity and format options to satisfy different UHPLC application requirements. They deliver:</p><ul><li><strong>Better Separations:</strong> high efficiency enables separation of very complex mixture</li><li><strong>More Results:</strong> High efficiency at high flow rates</li><li><strong>Easier Interactions:</strong> Seamless workflow solution, for simple and easy separations</li><li><strong>Wider Capabilities</strong>: Wide range of column selectivities and formats</li></ul><h4><strong>Specifications</strong></h4><ul><li><strong>Column type:</strong> Reversed Phase</li><li><strong>Endcapped:</strong> yes</li><li><strong>Max. Pressure:</strong> 21756 psi (1500 bar)</li><li><strong>Packing Material:</strong> Spherical, Fully Porous, Ultrapure Silica</li><li><strong>Stationary phase:</strong> C18</li><li><strong>USP Type:</strong> L1</li><li><strong>Surface Area:</strong> 300 m<sup>2</sup>/g</li><li><strong>Temperature:</strong> 60°C</li><li><strong>Carbon load: </strong>18%</li><li><strong>Phase:</strong> Reversed Phase</li><li><strong>Pore Size: </strong>120 Å</li><li><strong>pH: </strong>2 to 8</li></ul><h4><strong>About the Acclaim Family of HPLC Columns</strong></h4><p>Achieve the high standards set by modern HPLC and LC/MS methods with the Acclaim family of reversed-phase columns. These silica-based columns with advanced column bonding and endcapping technologies provide complementary selectivity, high column efficiencies, and ultra-high resolution for a wide variety of applications.</p><ul><li>Broad spectrum of stationary phases, including conventional C8 and C18 phases, polar embedded phases, and specialty phases including wide-pore, are available to meet your specific application needs</li><li>Performance tested to ensure high quality and reliability for pharmaceutical, biopharmaceutical, environmental, food, and other industrial chromatographic separations</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_Acclaim_column_Broad_range_of_HPLC_and_UHPLC_columns_2ec9c98a86.jpg" alt="Thermo Fisher Scientific: Broad range of HPLC and UHPLC columns" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_Acclaim_column_Broad_range_of_HPLC_and_UHPLC_columns_2ec9c98a86.jpg 191w," sizes="100vw" width="1172" height="958"></p>

Thermo Scientific Acclaim VANQUISH Polar Advantage II UHPLC Columns

Achieve even greater power of separation, speed, and throughput of polar and nonpolar compounds in a single run using Thermo Scientific Acclaim VANQUISH PA2 UHPLC columns.

<p><strong>Achieve even greater power of separation, speed, and throughput of polar and nonpolar compounds in a single run using Thermo Scientific™ Acclaim™ VANQUISH™ PA2 UHPLC columns. These reversed-phase columns were developed in conjunction with the </strong><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?category=40&amp;manufacturerItems=3&amp;search=vanquish"><strong>Vanquish UHPLC system</strong></a><strong> to take advantage of the system's extended pressure capabilities and robustness. The result is a new level of separation, speed and throughput that solve analytical challenges in liquid chromatography (LC) and LC-MS analyses. These Polar Advantage II columns provide selectivity that is complementary to conventional C18 columns.</strong></p><h5><strong>Delivering Powerful Separations</strong></h5><p>The expanded range of Thermo Scientific™ Accucore™ Vanquish™ and Acclaim VANQUISH UHPLC columns offer a wider range of selectivity and format options to satisfy different UHPLC application requirements. They deliver:</p><ul><li><strong>Better Separations:</strong> high efficiency enables separation of very complex mixture</li><li><strong>More Results:</strong> High efficiency at high flow rates</li><li><strong>Easier Interactions:</strong> Seamless workflow solution, for simple and easy separations</li><li><strong>Wider Capabilities</strong>: Wide range of column selectivities and formats</li></ul><h4><strong>Specifications</strong></h4><ul><li><strong>Column type:</strong> Reversed Phase</li><li><strong>Endcapped:</strong> yes</li><li><strong>For use with:</strong> LC/MS and RSLC</li><li><strong>Max. Pressure:</strong> 21756 psi (1500 bar)</li><li><strong>Packing Material:</strong> Spherical, Fully Porous, Ultrapure Silica</li><li><strong>Stationary phase:</strong> Polar</li><li><strong>USP Type:</strong> L60</li><li><strong>Surface Area:</strong> 300 m<sup>2</sup>/g</li><li><strong>Temperature:</strong> 60°C</li><li><strong>Carbon load: </strong>17%</li><li><strong>Phase:</strong> Reversed Phase</li><li><strong>Pore Size: </strong>120 Å</li><li><strong>pH: </strong>1.5 to 10</li></ul><h4><strong>About the Acclaim Family of HPLC Columns</strong></h4><p>Achieve the high standards set by modern HPLC and LC/MS methods with the Acclaim family of reversed-phase columns. These silica-based columns with advanced column bonding and endcapping technologies provide complementary selectivity, high column efficiencies, and ultra-high resolution for a wide variety of applications.</p><ul><li>Broad spectrum of stationary phases, including conventional C8 and C18 phases, polar embedded phases, and specialty phases including wide-pore, are available to meet your specific application needs</li><li>Performance tested to ensure high quality and reliability for pharmaceutical, biopharmaceutical, environmental, food, and other industrial chromatographic separations</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_Acclaim_column_Broad_range_of_HPLC_and_UHPLC_columns_2ec9c98a86.jpg" alt="Thermo Fisher Scientific: Broad range of HPLC and UHPLC columns" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_Acclaim_column_Broad_range_of_HPLC_and_UHPLC_columns_2ec9c98a86.jpg 191w," sizes="100vw" width="1172" height="958"></p>

Waters ACQUITY Arc LC System

The ACQUITY™ Arc™ System is an all-in-one platform for HPLC and UHPLC, designed for robust method development and seamless transfer between modern LC systems, addressing a wide range of analytical challenges.

<p class="cke-user_style-important"><strong>Built upon a foundation of reliability</strong></p><p data-pm-slice="1 1 []"><strong>The method development process is changing. New regulations, software and analytical technologies are rapidly changing how methods are designed, transferred, and monitored over their lifecycle. An all-in-one platform for HPLC and UHPLC separations, the ACQUITY™ Arc™ System is designed to meet the spectrum of challenges you face from robust method development to seamless transfer between any modern LC systems.</strong></p><p data-pm-slice="1 1 []">With the <strong>ACQUITY Arc System</strong>, you can experience true plug-and-play method compatibility for HPLC and UHPLC separations. Significant productivity gains can be realized by deploying a single LC platform that allows for the efficient transfer, adjustment, and improvement of methods from any LC platform without compromise in method integrity.</p><figure class="image"><img style="aspect-ratio:768/886;" src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_ACQUITY_Arc_System_63246061ea.jpg" alt="Waters ACQUITY Arc System" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_ACQUITY_Arc_System_63246061ea.jpg 136w," sizes="100vw" width="768" height="886"></figure><p data-pm-slice="1 1 []">Laboratory-driven organizations have relied on Waters for over 60 years to deliver reliable, robust, and reproducible solutions to ensure confidence in their analytical results. With over 100,000 LC systems installed, we understand the significant impact the right technology has on your business, and the implications it has on characterizing the quality and safety of your products.</p><p data-pm-slice="1 1 []">Methods with greater agility, robustness, and capacity for change can help you reduce regulatory burden, risk of failure and costs. Visit <a disabled="true">www.methods.waters.com</a> to learn more about how method life cycle management (MLCM) connects your method today to your method tomorrow.</p><h3><strong>Designed for discovery to routine QC applications</strong></h3><p>The <strong>ACQUITY Arc System</strong> is the only available LC system with regulatory compliant-ready hardware and software for both HPLC and UHPLC separations in one instrument. With unrivaled column capacity and Arc Multi-flow path™ technology, the<strong> ACQUITY Arc System</strong> allows you to generate new methods and modernize legacy HPLC methods faster than ever before.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_ACQUITY_Arc_System_2_c06ba42baa.jpg" alt="Waters ACQUITY Arc System: The ACQUITY Arc System can replicate your established HPLC methods by compensating for these differences with unique features such as the Arc Multi-Flow Path technology and Gradient SmartStart. These innovative attributes enable seamless replication of your existing chromatographic results to meet your acceptance criteria without changes to validated gradient tables." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_ACQUITY_Arc_System_2_c06ba42baa.jpg 234w," sizes="100vw" width="1024" height="682"></p><h4><strong>Comprehensive detector portfolio</strong></h4><p>High-performance analytical detectors designed to maximize HPLC and UHPLC performance, delivering exceptional sensitivity and linearity for your assays.</p><p>Photodiode array, UV/Vis, fluorescence, refractive index, evaporative light scattering, and mass detection, including the ACQUITY QDa™ Detector.</p><h4><strong>Gradient SmartStart</strong></h4><p>Automatically manage gradient start time and pre-injection steps to maximize sample throughput. Automatically counteract differences in system dwell volume without the need to alter gradient table inputs.</p><h4><strong>Quaternary solvent management</strong></h4><p>Precise and accurate blending of up to four solvents with automated solvent compressibility compensation. Increase solvent flexibility with an optional, integrated solvent select valve, providing access to six additional solvents.</p><h4><strong>Negligible carryover</strong></h4><p>Advanced flow-through needle design minimizes carryover by continuously cleansing the needle during run. User-configurable wash settings provide flexibility to address even the most complex sample matrices.</p><h4><strong>Thermal management options</strong></h4><p>Column manager options available for up to 15 columns ranging in length from 50 mm to 300 mm, with a temperature range of 4 °C to 90 °C. Integrated column selection valve options provide unattended, fast column changeover.</p><h4><strong>Auto•Blend™ Plus Technology</strong></h4><p>Program gradients directly in terms of pH and ionic strength to minimize manual mobile phase preparation, reduce potential for human error, and accelerate method robustness testing for chromatographic methods.</p><h4><strong>Arc Multi-flow path technology</strong></h4><p>Delivers plug-and-play method compatibility with HPLC or UHPLC methods with the flip of a switch.</p><p>Easily replicate or improve established methods by simply selecting between Path 1 (HPLC) or Path 2 (UHPLC) without any manual user intervention.</p><h4><strong>Column Technology</strong></h4><p>Industry-leading selectivity choices to meet the needs of virtually every LC application.</p><h4><strong>Laboratory Informatics</strong></h4><p>Software control within your existing Empower™ or MassLynx™ infrastructure.</p><h3><strong>Replicate your established methods</strong></h3><p data-pm-slice="1 1 []">The <strong>ACQUITY Arc System</strong>, enabled by unique Arc Multi-flow path technology, easily accepts and replicates methods from any HPLC platform, without compromise.&nbsp;</p><p data-pm-slice="1 1 []">Whether you are trying to replicate an out-of-date HPLC method, transfer methods across the organization, or to contract partners, the <strong>ACQUITY Arc System</strong> gives you ultimate flexibility to reproduce, modernize, and transfer existing methods with ease and greater cost efficiency, while preserving the integrity of your methods.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_ACQUITY_Arc_System_3_c8c7901de3.jpg" alt="Waters ACQUITY Arc System: Analysis run on a Vendor X LC system and replicated on the ACQUITY Arc System. Conditions: 15 to 35% B in 3 min, 35 to 95% B in 2 min; Mobile phase A: 0.1% HCOOH in H 2 O, mobile phase B: 0.1% HCOOH in ACN; Flow rate = 2.0 mL/min; Column: XSelect™ CSH C 18 , 4.6 x 150 mm, 5 μm; Temp. = 30 °C; UV@ 260 nm; 10.0 μL injection volume." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_ACQUITY_Arc_System_3_c8c7901de3.jpg 245w," sizes="100vw" width="1099" height="596"></p><p>Upgrade your laboratory with a versatile, modern LC system that delivers HPLC and UHPLC method compatibility at the flip of a switch.</p><h3><strong>Modernize your methods</strong></h3><p>The United States Pharmacopeia (USP) is championing pharmacopeial harmonization and modernization efforts, and international organizations are following suit. As a result, the USP is encouraging the modernization of older compendial methods to ensure they are fit for purpose.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_ACQUITY_Arc_System_4_a1aaab8d02.jpg" alt="Waters ACQUITY Arc System: Quetiapine fumarate system suitability solution analyzed on the ACQUITY Arc System using HPLC, UHPLC, and UPLC™ column/method conditions for the quetiapine impurity method. Peak identification: (1) quetiapine related compound G, (2) quetiapine related compound B, (3) quetiapine desethoxy, and (4) quetiapine." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_ACQUITY_Arc_System_4_a1aaab8d02.jpg 245w," sizes="100vw" width="1092" height="678"></p><p>Revisions to these guidelines give you more flexibility to modify your existing pharmacopeial methods with modern techniques and technologies, and in some cases avoid revalidation. The <strong>ACQUITY Arc System</strong>, featuring the Waters Columns Calculator, allows you to confidently scale your gradient methods from a 3.5 μm to a 2.5 μm particle, decreasing run times, lowering solvent consumption, and increasing sample throughput.</p><h3><span><strong>Save time. Reduce cost.</strong></span></h3><p data-pm-slice="1 1 []">With the right column, the <strong>ACQUITY Arc System</strong> is the ideal solution to accommodate methods from any LC platform.&nbsp;</p><p data-pm-slice="1 1 []">From concept to production, the transition your product takes through the product development cycle often requires rigorous LC assays to properly characterize and assess its readiness to advance to the next stage. These LC assays are often adapted to accommodate the technology available from one stage to the next, in some cases requiring an adjustment from a smaller particle size (sub-2-μm) to a larger particle size (2.5 μm–5 μm).</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_ACQUITY_Arc_System_5_d9dd95135c.jpg" alt="Waters ACQUITY Arc System: The ACQUITY Arc System enables the support of HPLC and UHPLC methods on a single platform." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_ACQUITY_Arc_System_5_d9dd95135c.jpg 173w," sizes="100vw" width="959" height="860"></p><p>The <strong>ACQUITY Arc System</strong> provides the flexibility to maximize productivity through efficient and rapid 2.5 μm–2.7 μm UHPLC separations, or to accommodate larger 3.0 μm–5 μm HPLC particles.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_ACQUITY_Arc_System_6_1ebc2c67e7.jpg" alt="Waters ACQUITY Arc System: Save time. Reduce cost." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_ACQUITY_Arc_System_6_1ebc2c67e7.jpg 245w," sizes="100vw" width="1683" height="469"></p><h3><span><strong>Mitigate your risk</strong></span></h3><p data-pm-slice="1 1 []">With an expanded range of column manager options enabling up to 15-column switching from 4 °C to 90 °C, the <strong>ACQUITY Arc System</strong> will help you significantly reduce the time spent generating robust methods. Equipped with the plug-and-play ACQUITY QDa Mass Detector, the <strong>ACQUITY Arc System</strong> tracks peaks in your method and reveals hidden coelutions of similar analytes, ensuring you have complete confidence in the reliability and reproducibility of your method now and far into the future.</p><h4><strong>Thermal management options</strong></h4><p data-pm-slice="1 1 []">Active and passive pre-heating options available, with up to 15-column switching from 4 °C to 90 °C. Automated monitoring and tracking of column usage with eCord™ technology available with active pre-heating options.</p><h4><strong>Quaternary solvent management</strong></h4><p data-pm-slice="1 1 []">Accelerate your method development with precise and accurate blending of up to four solvents. Increase solvent flexibility with an optional solvent select valve, providing access to six additional solvents.</p><h4><strong>Auto•Blend Plus Technology</strong></h4><p data-pm-slice="1 1 []">Reduce human error and accelerate method robustness testing for chromatographic methods by programming gradients to control mobile phase pH and ionic strength.</p><h4><strong>Comprehensive detector portfolio</strong></h4><p>Diverse portfolio of detectors for method development, method transfer, and routine use.</p><h4><strong>ACQUITY QDa Detector</strong></h4><p>Mass detection built around the needs of analytical scientists for chromatographic analysis. Robust, reliable and requiring no adjustments, it easily integrates with your<strong> ACQUITY Arc System.</strong></p><h5><strong>Support</strong></h5><p data-start="0" data-end="175">Empower eLearning modules to help train your lab on Empower 3 and Method Validation. Applications support that’s customized based on your method development needs.</p><h5><strong>Consumables</strong></h5><p data-start="177" data-end="410" data-is-last-node="">Industry-leading selectivity choices to meet the needs of virtually every LC application. Quality Control (QC) Reference Material benchmarks your <strong>ACQUITY Arc System </strong>and enables perfect resolution. Certified clean vials.</p><h5><strong>Laboratory Informatics</strong></h5><p>Software control within your existing Empower or MassLynx infrastructure. Empower 3 Method Validation Manager allows you to perform chromatographic method validation in one application. Optional S-Matrix Fusion Software automates your method development according to AQbD guidelines.</p><h3><span><strong>Develop methods that stand the test of time</strong></span></h3><p>Need an orthogonal detection approach to UV in your method development? Streamline your method development with an LC-MS solution that’s as easy to use as photodiode array detection.</p><p>The <strong>ACQUITY Arc System</strong> is fully compatible with the ACQUITY Arc, supporting efficient and robust method development by expanding the information you can get from your system using the same Empower Software. The system automatically pairs qualitative mass spectral data to the peaks in your chromatogram, leaving nothing to chance.</p><ul><li>Confirm the identity of peaks in a separation without injecting standards.</li><li>Identify new peaks in a separation with molecular weight information.&nbsp;</li><li>Detect unresolved peaks and determine if a peak is homogeneously pure.</li><li>Easily track peaks as method conditions are changed.</li></ul><p data-start="272" data-end="600">Using Empower 3 Software and its Custom Calculations and Custom Reporting functions enables you to quickly and automatically evaluate chromatographic data. Configurable reports allow you to choose optimal conditions based on metrics rather than judgment, ensuring a comprehensive assessment of data and best method conditions.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_ACQUITY_Arc_System_7_e7ef959203.jpg" alt="Waters ACQUITY Arc System: Method transfer of USP Assay for Fluconazole using the ACQUITY Arc System. Here the peak has same m/z of a related compound. Conditions: Mobile phase: 20:80 acetonitrile/ water; Flow rate = 0.5 mL/min; Column: XSelect HSS T3, 4.6 x 150 mm, 3.5 μm; UV@ 260 nm; 20.0 μL injection volume." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_ACQUITY_Arc_System_7_e7ef959203.jpg 224w," sizes="100vw" width="939" height="654"></p><h3><strong>Streamline your workflow</strong></h3><div><div data-message-author-role="assistant" data-message-id="7b732be9-0a45-45fb-b585-70a90c1a74d6" dir="auto" data-message-model-slug="gpt-4o"><div><div><p data-start="602" data-end="827">How would you benefit from increased assay consistency between analysts and from lab to lab? What would you gain by accelerating your robustness testing prior to transferring methods to QA/QC?</p><p data-start="829" data-end="1392" data-is-last-node="">Auto•Blend Plus Technology is a novel software tool that extends traditional quaternary solvent blending to permit gradient programming directly in units of pH and ionic strength, providing the ability to vary composition in even the smallest increments of pH (even those differing by 0.1 pH units or less).&nbsp;</p><p data-start="829" data-end="1392" data-is-last-node="">With Auto•Blend Plus, the cumbersome and error-prone approach of manually preparing several pre-mixed mobile phases can now be eliminated with on-demand mobile phase creation, providing significant time savings and improved productivity to the laboratory.</p></div></div></div></div>

Thermo Scientific Syncronis C18 Columns

Achieve repeatable and consistent liquid chromatography (LC) separations using Thermo Scientific™ Syncronis™ C18 columns. 

<p><strong>Achieve repeatable and consistent liquid chromatography (LC) separations using Thermo Scientific™ Syncronis™ C18 columns. Highly pure, high surface area silica and dense stationary phase coverage minimize secondary interactions and ensure robust, high-resolution separations.&nbsp;</strong></p><p>Double end-capping provides extra surface coverage and inertness toward basic compounds. Manufactured and rigorously tested in ISO 9000 facilities, these columns are designed to meet a range of analytical needs including fast method development, quantitative analysis, and quality control.</p><h5><strong>Highly Reproducible Separations</strong></h5><ul><li>Rigorously tested stationary phase bonded to the highest quality silica ensures consistent, predictable LC performance.</li></ul><h5><strong>Excellent Peak Shapes for Enhanced Resolution and Sensitivity</strong></h5><ul><li>Dense surface coverage of silica minimizes secondary interactions and peak tailing</li><li>Double endcapped for extra surface coverage</li></ul><h5><strong>Exceptional Column-to-Column Consistency</strong></h5><ul><li>Manufactured, packed, and tested in ISO-9000-accredited facilities</li><li>Every column individually tested to meet stringent retention, efficiency, and peak symmetry specifications</li><li>Enhanced automated packing process</li></ul><h5><strong>Available in Three Particle Sizes</strong></h5><ul><li>1.7 μm for rapid ultrahigh-performance LC (UHPLC) separations, and 3 μm and 5 μm for more traditional HPLC analysis</li></ul><h4><strong>Specifications</strong></h4><ul><li><strong>Column type:</strong> Reversed Phase</li><li><strong>Endcapped:</strong> yes</li><li><strong>Max. Pressure:</strong> 5800 psi (400 bar)</li><li><strong>Packing Material:</strong> Spherical, Fully Porous, Ultrapure Silica</li><li><strong>Stationary phase:</strong> C18</li><li><strong>USP Type:</strong> L1</li><li><strong>Surface Area:</strong> 320 m<sup>2</sup>/g</li><li><strong>Temperature:</strong> 60°C</li><li><strong>Carbon load: </strong>16%</li><li><strong>Phase:</strong> Reversed Phase</li><li><strong>Pore Size: </strong>100 Å</li><li><strong>pH: </strong>2 to 9</li></ul><h4><strong>Syncronis HPLC and UHPLC Columns</strong></h4><h5><strong>Enter a new world of chromatography</strong></h5><p>When developing a new method, one of the most important goals for the chromatographer is to achieve a consistent, reproducible separation. This makes selecting an HPLC column that offers highly-reproducible results essential to attaining this goal.</p><h5><strong>Features of Syncronis columns</strong></h5><p>Thermo Scientific Syncronis LC columns achieve high levels of consistency and reproducibility through:</p><ul><li>Highly-pure, high-surface-area silica</li><li>Dense bonding and double endcapping</li><li>Stringent manufacturing and testing protocols</li></ul>

Thermo Scientific Syncronis C18 HPLC Columns

Attain repeatable and consistent LC separations for your scale up purification needs with Thermo Scientific™ Syncronis™ C18 reversed phase preparative HPLC columns. 

<p><strong>Attain repeatable and consistent LC separations for your scale up purification needs with Thermo Scientific™ Syncronis™ C18 reversed phase preparative HPLC columns. These preparative HPLC columns have extremely pure, high surface area silica with dense stationary phase coverage to minimize secondary interactions and ensure robust, high-resolution separations. Double endcapping provides additional surface coverage and inertness toward basic compounds. Columns come in a variety of dimensions and an option for XtendedLife hardware which improves column lifetime by maintaining a uniform packed bed.</strong></p><h5><strong>Highly Reproducible Separations</strong></h5><ul><li>Rigorously tested stationary phase bonded to the highest quality silica ensures consistent, predictable LC performance.</li></ul><h5><strong>Enhanced Resolution and Sensitivity</strong></h5><ul><li>Dense surface coverage of silica minimizes secondary interactions and peak tailing.</li><li>Double endcapped for extra surface coverage.<br>C18 (USP L1) selectivity.</li></ul><p><strong>Preparative HPLC Column Hardware Options</strong> - based on column inner diameter (i.d.) and column performance needs.</p><h5><strong>Standard Threaded and Standard Flange Hardware</strong></h5><ul><li>Designed for standard applications, expertly packed and robustly designed to provide versatile products for routine use.</li><li>Standard threaded hardware for column i.d. &lt; 40mm.</li><li>Standard flange hardware for column i.d. ≥ 40mm.</li><li>Standard hardware can be modified on request to be compatible with SFC.</li></ul><h5><strong>XtendedLife Hardware</strong></h5><ul><li>Improves column lifetime by incorporating an internal Dynamic Axial Compression (DAC) system, ensuring the media bed is continuously packed tightly.</li><li>Compatible with SFC and is available in dimensions up to 50mm i.d.</li></ul><p>Preparative Guards are a proven and cost effective way to extend the lifetime of your prep column. Our preparative guard columns require the use of a preparative guard holder.</p><h5><strong>Customer Specific Orders</strong></h5><p>If there is a Thermo Scientific stationary phase you are currently using and would like to obtain in a preparative scale not shown or would like to discuss a specific column dimension, we would be happy to discuss your requirements.<br>Please contact your local sales representative for Customer Specific Orders.<br>Custom built columns are not eligible for returns.</p><h4><strong>Specifications</strong></h4><ul><li><strong>Column type:</strong> Reversed Phase</li><li><strong>Endcapped:</strong> yes</li><li><strong>Max. Pressure:</strong> 4300 psi (295 bar)</li><li><strong>Packing Material:</strong> Spherical, Fully Porous, Ultrapure Silica</li><li><strong>Stationary phase:</strong> C18</li><li><strong>USP Type:</strong> L1</li><li><strong>Surface Area:</strong> 320 m<sup>2</sup>/g</li><li><strong>Temperature:</strong> 60°C</li><li><strong>Carbon load: </strong>16%</li><li><strong>Phase:</strong> Reversed Phase</li><li><strong>Pore Size: </strong>100 Å</li><li><strong>pH: </strong>2 to 9</li></ul><h4><strong>Syncronis HPLC and UHPLC Columns</strong></h4><h5><strong>Enter a new world of chromatography</strong></h5><p>When developing a new method, one of the most important goals for the chromatographer is to achieve a consistent, reproducible separation. This makes selecting an HPLC column that offers highly-reproducible results essential to attaining this goal.</p><h5><strong>Features of Syncronis columns</strong></h5><p>Thermo Scientific Syncronis LC columns achieve high levels of consistency and reproducibility through:</p><ul><li>Highly-pure, high-surface-area silica</li><li>Dense bonding and double endcapping</li><li>Stringent manufacturing and testing protocols</li></ul>

Thermo Scientific Syncronis C8 HPLC Columns

Improve the consistency and reliability of your liquid chromatography (LC) separations using Thermo Scientific™ Syncronis™ C8 LC columns.

<p><strong>Improve the consistency and reliability of your liquid chromatography (LC) separations using Thermo Scientific™ Syncronis™ C8 LC columns. High-purity, high surface area silica and dense stationary phase coverage minimize secondary interactions and deliver reproducible, high-efficiency separations.&nbsp;</strong></p><p>Double end-capping provides extra surface coverage and inertness toward basic compounds. Manufactured and rigorously tested in ISO 9000 facilities, these columns are designed to meet a range of analytical needs including fast method development, quantitative analysis, and quality control where less retention is required than when using a C18 column.</p><h5><strong>Excellent Peak Shapes for Enhanced Resolution and Sensitivity</strong></h5><ul><li>Dense surface coverage of silica minimizes secondary interactions and peak tailing</li><li>Double endcapped for extra surface coverage</li></ul><h5><strong>Exceptional Column-to-Column Consistency</strong></h5><ul><li>Manufactured, packed, and tested in ISO-9000-accredited facilities</li><li>Every column individually tested to meet stringent retention, efficiency, and peak symmetry specifications</li><li>Enhanced automated packing process</li></ul><h5><strong>Lower Hydrophobic Retention</strong></h5><ul><li>Recommended for moderately hydrophobic analytes or for when a less hydrophobic phase provides optimum retention</li></ul><h5><strong>Available in Three Particle Sizes</strong></h5><ul><li>1.7 μm for rapid ultrahigh-performance LC (UHPLC) separations, and 3 μm and 5 μm for more traditional HPLC analysis</li></ul><h4><strong>Specifications</strong></h4><ul><li><strong>Column type:</strong> Reversed Phase</li><li><strong>Endcapped:</strong> yes</li><li><strong>Max. Pressure:</strong> 5800 psi (400 bar)</li><li><strong>Packing Material:</strong> Spherical, Fully Porous, Ultrapure Silica</li><li><strong>Stationary phase:</strong> C8</li><li><strong>USP Type:</strong> L7</li><li><strong>Surface Area:</strong> 320 m<sup>2</sup>/g</li><li><strong>Temperature:</strong> 60°C</li><li><strong>Carbon load: </strong>10%</li><li><strong>Phase:</strong> Reversed Phase</li><li><strong>Pore Size: </strong>100 Å</li><li><strong>pH: </strong>2 to 8</li></ul><h4><strong>Syncronis HPLC and UHPLC Columns</strong></h4><h5><strong>Enter a new world of chromatography</strong></h5><p>When developing a new method, one of the most important goals for the chromatographer is to achieve a consistent, reproducible separation. This makes selecting an HPLC column that offers highly-reproducible results essential to attaining this goal.</p><h5><strong>Features of Syncronis columns</strong></h5><p>Thermo Scientific Syncronis LC columns achieve high levels of consistency and reproducibility through:</p><ul><li>Highly-pure, high-surface-area silica</li><li>Dense bonding and double endcapping</li><li>Stringent manufacturing and testing protocols</li></ul>

Thermo Scientific Syncronis HILIC HPLC Columns

Ensure consistent, predictable separations of polar and hydrophilic analytes with Thermo Scientific™ Syncronis™ HILIC LC Columns. 

<p><strong>Ensure consistent, predictable separations of polar and hydrophilic analytes with Thermo Scientific™ Syncronis™ HILIC LC Columns. Highly pure, high surface area silica and dense stationary phase coverage minimize secondary interactions and deliver reproducible high-resolution separations. The zwitterionic stationary phase results in a neutral, highly polar surface and provides alternative selectivity to C18 columns without ion-pairing or derivatization. The highly organic mobile phases used with Syncronis HILIC phases facilitate efficient desolvation in ESI-MS detection and improved sensitivity.</strong></p><p>Manufactured and rigorously tested in ISO 9000 facilities, these columns are designed to meet a range of analytical needs including fast method development, quantitative analysis and quality control.</p><h5><strong>Highly Reproducible Separations</strong></h5><ul><li>Rigorously tested stationary phase bonded to the highest quality silica ensures consistent, predictable LC performance</li></ul><h5><strong>Excellent Peak Shapes for Enhanced Resolution and Sensitivity</strong></h5><ul><li>Dense surface coverage of silica minimizes secondary interactions and peak tailing</li></ul><h5><strong>Exceptional Column-to-Column Consistency</strong></h5><ul><li>Manufactured, packed, and tested in ISO-9000-accredited facilities</li><li>Every column individually tested to meet stringent retention, efficiency, and peak symmetry specifications</li><li>Enhanced automated packing process</li></ul><h5><strong>Alternative Selectivity</strong></h5><ul><li>Zwitterionic bonded phase enhances retention of polar and hydrophilic analytes</li><li>No need for ion-pair or derivatization</li></ul><h5><strong>Enhanced Sensitivity with MS Detection</strong></h5><ul><li>Highly organic mobile phase facilitates desolvation in ESI-MS</li></ul><h5><strong>Available in Three Particle Sizes</strong></h5><ul><li>1.7μm for rapid ultrahigh-performance LC (UHPLC) separations</li><li>3μm and 5μm for more traditional HPLC analysis</li></ul><h4><strong>Specifications</strong></h4><ul><li><strong>Column type:</strong> HILIC</li><li><strong>Max. Pressure:</strong> 5800 psi (400 bar)</li><li><strong>Packing Material:</strong> Spherical, Fully Porous, Ultrapure Silica</li><li><strong>Stationary phase:</strong> Zwitterionic</li><li><strong>Surface Area:</strong> 320 m<sup>2</sup>/g</li><li><strong>Temperature:</strong> 60°C</li><li><strong>Carbon load: </strong>5%</li><li><strong>Phase:</strong> HILIC</li><li><strong>Pore Size: </strong>100 Å</li><li><strong>pH: </strong>2 to 8</li></ul><h4><strong>Syncronis HPLC and UHPLC Columns</strong></h4><h5><strong>Enter a new world of chromatography</strong></h5><p>When developing a new method, one of the most important goals for the chromatographer is to achieve a consistent, reproducible separation. This makes selecting an HPLC column that offers highly-reproducible results essential to attaining this goal.</p><h5><strong>Features of Syncronis columns</strong></h5><p>Thermo Scientific Syncronis LC columns achieve high levels of consistency and reproducibility through:</p><ul><li>Highly-pure, high-surface-area silica</li><li>Dense bonding and double endcapping</li><li>Stringent manufacturing and testing protocols</li></ul>

Thermo Scientific Syncronis aQ C18 Polar Endcapped HPLC Columns

The polar end-capped C18 phase in Thermo Scientific Syncronis aQ Column provides optimal retention of polar analytes and is fully compatible with 100% aqueous mobile phases. 

<p><strong>Ensure consistent, predictable liquid chromatography (LC) separations of polar analytes using Thermo Scientific™ Syncronis™ aQ Columns. High surface area silica and dense stationary phase coverage minimize secondary interactions and deliver reproducible high-resolution separations. The polar end-capped C18 phase provides optimal retention of polar analytes and is fully compatible with 100% aqueous mobile phases. Manufactured and rigorously tested in ISO 9000 facilities, these columns are designed to meet a range of analytical needs including fast method development, quantitative analysis, and quality control.</strong></p><h5><strong>Highly Reproducible Separations</strong></h5><ul><li>Rigorously tested stationary phase bonded to the highest quality silica ensures consistent, predictable LC performance</li></ul><h5><strong>Excellent Peak Shapes for Enhanced Resolution and Sensitivity</strong></h5><ul><li>Dense surface coverage of silica minimizes secondary interactions and peak tailing</li></ul><h5><strong>Exceptional Column-to-Column Consistency</strong></h5><ul><li>Manufactured, packed, and tested in ISO-9000-accredited facilities</li><li>Every column individually tested to meet stringent retention, efficiency, and peak symmetry specifications</li><li>Enhanced automated packing process</li></ul><h5><strong>Alternative Selectivity</strong></h5><ul><li>Polar end-capped C18 stationary phase enhances retention of polar analytes</li></ul><h5><strong>Compatible with Highly Aqueous Mobile Phases</strong></h5><ul><li>Polar end-capping allows use of 100% aqueous mobile phases without loss of performance or stability</li></ul><h5><strong>Available in Three Particle Sizes</strong></h5><ul><li>1.7μm for rapid ultrahigh-performance LC (UHPLC) separations</li><li>3μm and 5μm for more traditional HPLC analysis</li></ul><h4><strong>Specifications</strong></h4><ul><li><strong>Column type:</strong> Reversed Phase</li><li><strong>Endcapped: </strong>Polar</li><li><strong>Max. Pressure:</strong> 5800 psi (400 bar)</li><li><strong>Packing Material:</strong> Spherical, Fully Porous, Ultrapure Silica</li><li><strong>Stationary phase:</strong> C18</li><li><strong>USP Type:</strong> L1</li><li><strong>Surface Area:</strong> 320 m<sup>2</sup>/g</li><li><strong>Temperature:</strong> 60°C</li><li><strong>Carbon load: </strong>19%</li><li><strong>Phase:</strong> Reversed Phase</li><li><strong>Pore Size: </strong>100 Å</li><li><strong>pH: </strong>2 to 8</li></ul><h4><strong>Syncronis HPLC and UHPLC Columns</strong></h4><h5><strong>Enter a new world of chromatography</strong></h5><p>When developing a new method, one of the most important goals for the chromatographer is to achieve a consistent, reproducible separation. This makes selecting an HPLC column that offers highly-reproducible results essential to attaining this goal.</p><h5><strong>Features of Syncronis columns</strong></h5><p>Thermo Scientific Syncronis LC columns achieve high levels of consistency and reproducibility through:</p><ul><li>Highly-pure, high-surface-area silica</li><li>Dense bonding and double endcapping</li><li>Stringent manufacturing and testing protocols</li></ul>

Thermo Scientific Syncronis Silica HPLC Columns

Optimize the reproducibility of normal phase chromatographic separations using Thermo Scientific™ Syncronis™ Silica LC Columns.

<p><strong>Optimize the reproducibility of normal phase chromatographic separations using Thermo Scientific™ Syncronis™ Silica LC Columns. Highly pure, base-deactivated, high surface area silica media ensure robust, high-resolution separations of nonpolar and moderately polar organic compounds by normal phase chromatography.</strong></p><p>Manufactured and rigorously tested in ISO 9000 facilities, these columns are designed to meet a range of analytical needs including fast method development, quantitative analysis and quality control.</p><h5><strong>Excellent Reproducibility in Normal Phase Chromatography</strong></h5><ul><li>Highest quality silica ensure consistent, predictable LC performance</li><li>Exceptional Column-to-Column Consistency</li><li>Manufactured, packed and tested in ISO-9000-accredited facilities</li><li>Every column individually tested to meet stringent retention, efficiency and peak symmetry specifications</li><li>Enhanced automated packing process</li></ul><h5><strong>Available in Three Particle Sizes</strong></h5><ul><li>1.7μm for rapid ultrahigh-performance LC (UHPLC) separations</li><li>3μm and 5μm for more traditional HPLC analysis</li></ul><h4><strong>Specifications</strong></h4><ul><li><strong>Column type:</strong> Normal Phase</li><li><strong>Max. Pressure:</strong> 5800 psi (400 bar)</li><li><strong>Packing Material:</strong> Spherical, Fully Porous, Ultrapure Silica</li><li><strong>Stationary phase:</strong> Silica</li><li><strong>USP Type:</strong> L3</li><li><strong>Surface Area:</strong> 320 m<sup>2</sup>/g</li><li><strong>Temperature:</strong> 60°C</li><li><strong>Phase:</strong> Normal Phase</li><li><strong>Pore Size: </strong>100 Å</li><li><strong>pH: </strong>2 to 8</li></ul><h4><strong>Syncronis HPLC and UHPLC Columns</strong></h4><h5><strong>Enter a new world of chromatography</strong></h5><p>When developing a new method, one of the most important goals for the chromatographer is to achieve a consistent, reproducible separation. This makes selecting an HPLC column that offers highly-reproducible results essential to attaining this goal.</p><h5><strong>Features of Syncronis columns</strong></h5><p>Thermo Scientific Syncronis LC columns achieve high levels of consistency and reproducibility through:</p><ul><li>Highly-pure, high-surface-area silica</li><li>Dense bonding and double endcapping</li><li>Stringent manufacturing and testing protocols</li></ul>

Thermo Scientific Syncronis Amino HPLC Columns

Improve the consistency and reliability of your liquid chromatography (LC) separations with Thermo Scientific™ Syncronis™ Amino LC Columns.

<p><strong>Improve the consistency and reliability of your liquid chromatography (LC) separations with Thermo Scientific™ Syncronis™ Amino LC Columns. Manufactured and rigorously tested in ISO 9000 facilities, these columns are designed to meet a range of analytical needs including fast method development, quantitative analysis and quality control.</strong></p><p>High surface area silica, dense stationary phase coverage and double end-capping minimize secondary interactions and ensure reproducible high-resolution separations.</p><h5><strong>Highly Reproducible Separations</strong></h5><ul><li>Rigorously tested stationary phase bonded to the highest quality silica ensures consistent, predictable LC performance.</li></ul><h5><strong>Excellent Peak Shapes for Enhanced Resolution and Sensitivity</strong></h5><ul><li>Dense surface coverage of silica minimizes secondary interactions and peak tailing</li><li>Double endcapped for extra surface coverage</li></ul><h5><strong>Exceptional Column-to-Column Consistency</strong></h5><ul><li>Manufactured, packed and tested in ISO-9000-accredited facilities</li><li>Every column individually tested to meet stringent retention, efficiency, and peak symmetry specifications</li><li>Enhanced automated packing process</li></ul><h5><strong>Excellent Performance in Four Modes</strong></h5><ul><li>Aminopropyl phase performs well in reversed phase, normal phase, weak ion exchange and HILIC modes</li></ul><h5><strong>Available in Three Particle Sizes</strong></h5><ul><li>1.7μm for rapid ultrahigh-performance LC (UHPLC) separations</li><li>3μm and 5μm for more traditional HPLC analysis</li></ul><h4><strong>Specifications</strong></h4><ul><li><strong>Column type:</strong> Mixed mode</li><li><strong>Endcapped: </strong>Yes</li><li><strong>Max. Pressure:</strong> 5800 psi (400 bar)</li><li><strong>Packing Material:</strong> Spherical, Fully Porous, Ultrapure Silica</li><li><strong>Stationary phase:</strong> Amino (NH2)</li><li><strong>USP Type:</strong> L8</li><li><strong>Surface Area:</strong> 320 m<sup>2</sup>/g</li><li><strong>Temperature:</strong> 60°C</li><li><strong>Carbon load:</strong> 4%</li><li><strong>Phase:</strong> Reversed Phase, Normal Phase, Ion Exchange, HILIC</li><li><strong>Pore Size: </strong>100 Å</li><li><strong>pH: </strong>2 to 8</li></ul><h4><strong>Syncronis HPLC and UHPLC Columns</strong></h4><h5><strong>Enter a new world of chromatography</strong></h5><p>When developing a new method, one of the most important goals for the chromatographer is to achieve a consistent, reproducible separation. This makes selecting an HPLC column that offers highly-reproducible results essential to attaining this goal.</p><h5><strong>Features of Syncronis columns</strong></h5><p>Thermo Scientific Syncronis LC columns achieve high levels of consistency and reproducibility through:</p><ul><li>Highly-pure, high-surface-area silica</li><li>Dense bonding and double endcapping</li><li>Stringent manufacturing and testing protocols</li></ul>

Related content

Dissecting Heterogeneous Populations of Protein-Complex Samples Using Direct Mass Technology

Webinars LabRulezLCMS Week 07/2026

Affinity, Gel Filtration, Size Exclusion Chromatography: Repurposing Kinase Inhibitors for Malaria